Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02662556 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
A Phase 3 study of Acute Moderate-to-severe Pain, sponsored by Talphera.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT02662556 is a Phase 3 study of Acute Moderate-to-severe Pain that has completed, run by Talphera. The registered enrollment target is 140 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02662556, a Phase 3 study of Acute Moderate-to-severe Pain, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure. Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
Conditions Studied
Interventions
- DRUG sufentanil sublingual tablet 30 mcg
Study Locations (2)
Texas
- HD Research - Houston
- Research Concepts - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02662556
The ClinicalTrials.gov registry entry for NCT02662556 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Moderate-to-severe Pain appearing as the primary indexed condition, and to 1 intervention - of which sufentanil sublingual tablet 30 mcg is the first listed.
NCT02662556 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02662556 about?
NCT02662556 is a clinical study titled "A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain". This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure. Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
What is the current status of trial NCT02662556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2016-03. Estimated completion is 2016-07.
What conditions does trial NCT02662556 study?
This clinical trial studies the following conditions: Acute Moderate-to-severe Pain.
What interventions are being tested in trial NCT02662556?
The interventions under investigation include: sufentanil sublingual tablet 30 mcg (DRUG).
Who is sponsoring clinical trial NCT02662556?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02662556 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.